Pfizer has sold a further 700 million ordinary shares in Haleon, its former joint venture with GSK in consumer healthcare products.

In a financial notice, Haleon states that the American pharmaceutical group placed its shares on the market at a unit price of 357 pence (or around $4.36), corresponding to total proceeds of some £2.5 billion (or $3.05 billion).

With this transaction, Pfizer's stake in Haleon will be reduced from 15% to 7.3%, as the American healthcare giant plans to eventually divest its entire stake, which initially stood at 32%.

Copyright (c) 2025 CercleFinance.com. All rights reserved.